Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Viral Matters focuses on all aspects of Direct Acting Antivirals (DAA) and Antiretrovirals in development and on the market.
Pages
Search This Blog
About Me
- Chris Barnes
- Redondo Beach, CA, United States
- A 17 year veteran of Medical Affairs and Commercial functions of the biopharma and pharmaceutical industry, with expertise in Hepatitis and HIV. christopherjbarnes10@gmail.com
Posts
Followers
Blog Archive
-
▼
2011
(194)
-
▼
June
(14)
- P7 inhibitors face low barrier to resistance in HC...
- From NATAP.org: HCV Treaters Shortage Editorial - ...
- Join "Viral Matters" HCV drug development discussi...
- Medivir/Tibotec's NS5B Inhibitor TMC649128 starts ...
- NPR's "Talk of the Nation" interviews Dr. John War...
- NATAP presents "New Advances in Hep C Therapy: The...
- Axium Healthcare Pharmacy Adds New Hepatitis C Dru...
- Vertex licenses early-stage polymerase inhibitors...
- Diana Sylvestre article on the possibilities of HC...
- Pharmasset Announces the Expansion of the ELECTRON...
- Heavy Coffee Consumption Linked to Better Hep C Tr...
- Analysts speculate on PSI-7977 possibly receiving ...
- Ever wonder who came up with the brand name "Inciv...
- New trials looking at treating HCV genotypes 1,2,3...
-
▼
June
(14)
No comments:
Post a Comment